These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24747233)

  • 1. The role of academic medical centers in advancing regulatory science.
    Meyer RJ
    Clin Pharmacol Ther; 2014 May; 95(5):471-3. PubMed ID: 24747233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of academic medicine for innovations in development of drugs and biomedicine technology].
    Manns MP
    Dtsch Med Wochenschr; 2013 Oct; 138(40):1993-4. PubMed ID: 24065403
    [No Abstract]   [Full Text] [Related]  

  • 3. Translational research: moving discovery to practice.
    Zerhouni EA
    Clin Pharmacol Ther; 2007 Jan; 81(1):126-8. PubMed ID: 17186011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership.
    Stang PE; Ryan PB; Racoosin JA; Overhage JM; Hartzema AG; Reich C; Welebob E; Scarnecchia T; Woodcock J
    Ann Intern Med; 2010 Nov; 153(9):600-6. PubMed ID: 21041580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Collaborating with industry--choices for the academic medical center.
    Moses H; Braunwald E; Martin JB; Thier SO
    N Engl J Med; 2002 Oct; 347(17):1371-5. PubMed ID: 12397200
    [No Abstract]   [Full Text] [Related]  

  • 7. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is it possible for FDA regulatory scientists and industry scientists to work together?
    Woosley RL
    Clin Pharmacol Ther; 2012 Mar; 91(3):390-2. PubMed ID: 22343817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tapping Into Valuable Expertise From Private Practitioners and Academicians: Casting a Wider Net.
    Eydelman MB; Saha A; Tarver ME
    JAMA Ophthalmol; 2015 Aug; 133(8):865-6. PubMed ID: 25996586
    [No Abstract]   [Full Text] [Related]  

  • 10. Translational Research and Drug Development in Psoriasis by Collaborative Efforts of Academia and Industry.
    van de Kerkhof PCM
    J Invest Dermatol; 2020 Mar; 140(3):524-526. PubMed ID: 31945346
    [No Abstract]   [Full Text] [Related]  

  • 11. Allied against reform: pharmaceutical industry-academic physician relations in the United States, 1945-1970.
    Tobbell DA
    Bull Hist Med; 2008; 82(4):878-912. PubMed ID: 19075387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Academic medical centers and the pharmaceutical industry.
    Del Parigi A
    Clin Pharmacol Ther; 2010 Oct; 88(4):464-5. PubMed ID: 20703224
    [No Abstract]   [Full Text] [Related]  

  • 13. Conflict of interest or productive collaboration? The pharma: academic relationship and its implications for headache medicine.
    Finkel AG
    Headache; 2006; 46(7):1181-5. PubMed ID: 16866722
    [No Abstract]   [Full Text] [Related]  

  • 14. Mission possible: managing innovation in drug discovery.
    Zhong X; Moseley GB
    Nat Biotechnol; 2007 Aug; 25(8):945-6. PubMed ID: 17687373
    [No Abstract]   [Full Text] [Related]  

  • 15. Building a new biomedical ecosystem: Pfizer's Centers for Therapeutic Innovation.
    Patel AC; Coyle AJ
    Clin Pharmacol Ther; 2013 Sep; 94(3):314-6. PubMed ID: 23645247
    [No Abstract]   [Full Text] [Related]  

  • 16. Regulation and Innovation: Role of Regulatory Science in Facilitating Pharmaceutical Innovation.
    Honig P; Zhang L
    Clin Pharmacol Ther; 2019 Apr; 105(4):778-781. PubMed ID: 30883715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Institutional review boards and collaborations between academia and industry: some counterproductive policies and practices.
    Levine RJ
    Circulation; 1985 Aug; 72(2 Pt 2):I48-50. PubMed ID: 4006159
    [No Abstract]   [Full Text] [Related]  

  • 18. Steve Carney talks to Vincent Lee on the pharma industry, the FDA and public education with respect to drugs and their development.
    Lee VH
    Drug Discov Today; 2005 Nov; 10(21):1411-4. PubMed ID: 16243258
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmaceuticals and medical devices: FDA oversight.
    ; Berry MD
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-86. PubMed ID: 22403845
    [No Abstract]   [Full Text] [Related]  

  • 20. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.
    Woosley RL; Myers RT; Goodsaid F
    Clin Pharmacol Ther; 2010 May; 87(5):530-3. PubMed ID: 20407457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.